Lyell Immunopharma, Inc. - LYEL STOCK NEWS

Lyell Immunopharma reported significant financial updates for Q2 2022, with revenue climbing to $35.7 million, a notable increase from $2.6 million in Q2 2021. This surge is attributed to a mutual agreement with GSK for a hematological cancer research initiative. Despite a net loss of $36.3 million, an improvement from $62.6 million in the prior year, Lyell's cash position remains strong at $787 million, expected to fund operations through 2025. The company continues to advance its clinical pipeline, focusing on overcoming T-cell exhaustion in solid tumor therapies.

Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage T-cell reprogramming company, will participate in the Goldman Sachs 43rd Annual Global Healthcare Conference on June 14 at 10:40 AM PT. A live webcast of the event will be available on the company’s website, with a replay accessible for 90 days afterward. Lyell focuses on developing curative cell therapies for solid tumors and utilizes proprietary technologies to enhance T-cell functionality. For more information, visit www.lyell.com.

Lyell Immunopharma reported a first-quarter net loss of $68.1 million for Q1 2022, up from $55.0 million in Q1 2021. The company holds $838 million in cash and marketable securities, expected to cover operations through 2025. Lyell advanced two products into Phase 1 clinical development and plans to submit INDs for LYL845 and LYL331 later this year. R&D expenses decreased to $35.8 million, while G&A expenses rose sharply to $34.4 million, driven by stock-based compensation and litigation costs. Upcoming presentations at ASGCT and AACR are expected to highlight advancements in their cell therapy pipeline.

Lyell Immunopharma, Inc. (Nasdaq: LYEL), a leader in T-cell reprogramming, announced participation in the BofA Securities 2022 Healthcare Conference on May 11 at 5:20 pm PT. The management team will engage in a fireside chat that can be accessed via a live webcast on the company's investor relations page. A replay will be available for 90 days after the event. Lyell focuses on overcoming challenges in adoptive T-cell therapy, utilizing proprietary technologies Gen-R and Epi-R to enhance T-cell functionality for combating solid tumors.

Lyell Immunopharma (Nasdaq: LYEL) announced two abstracts accepted for poster presentations at the 25th Annual Meeting of the American Society of Gene & Cell Therapy, from May 16 to May 19, 2022. The presentations will showcase preclinical data on LYL797 and LYL132, both in Phase 1 trials, focusing on Gen-R and Epi-R technologies that enhance T-cell performance against solid tumors. LYL797 targets ROR1-positive cancers, while LYL132 targets NY-ESO-1 expressing tumors. The aim is to improve T-cell durability and anti-tumor effectiveness.

Lyell Immunopharma (Nasdaq: LYEL) reported its 2021 financial results, highlighting a net loss of $250.2 million. Cash, equivalents, and marketable securities totaled $898 million as of Dec 31, 2021, supporting their cell therapy pipeline. The company received FDA clearance for two INDs and is initiating clinical trials for therapies targeting solid tumors. Key R&D expenses decreased to $138.7 million from $182.2 million in 2020. The team was strengthened with new executive appointments. Positive long-term outlook with cash expected to sustain operations until at least 2025.

Lyell Immunopharma has announced that its investigational LYL797, a ROR1 CAR T-cell therapy, will be presented at the AACR 2022 Annual Meeting from April 8-13 in New Orleans. The therapy employs advanced T-cell reprogramming technologies aimed at treating solid tumors. Preclinical data will be highlighted, showcasing Gen-R and Epi-R technologies that enhance T-cell durability and functionality. The poster presentation is scheduled for April 12, featuring Spencer Park, PhD.

LYL797 has received FDA clearance for Phase 1 clinical trials.

Lyell Immunopharma, Inc. (Nasdaq: LYEL) has appointed Gary Lee, Ph.D., as its new Chief Scientific Officer. Dr. Lee brings over a decade of experience in translational cell and gene therapy, aiming to advance the company’s research pipeline. This strategic move reflects Lyell's commitment to developing a multi-modality cell therapy pipeline using its innovative T-cell reprogramming technologies. Concurrently, Nick Restifo will transition to a scientific advisor role, continuing to support the company's programs.

Lyell Immunopharma announced the FDA has cleared an IND application to start a Phase 1 clinical trial for LYL132, a T-cell receptor therapy targeting NY-ESO-1 in patients with solid tumors. This therapy utilizes Lyell’s Epi-R technology, aimed at overcoming barriers in adoptive cell therapy by promoting T cell properties of durable stemness. The clinical trial will focus on advanced synovial sarcoma and myxoid/round cell liposarcoma. This clearance marks a significant milestone for Lyell, indicating progress in their collaboration with GSK and their commitment to cancer drug development.